Abstract Library

#4113 Establishment of a rat model of diarrhea induced by Surufatinib

Introduction: Surufatinib is a novel oral small-molecule TKI for the treatment of advanced neuroendocrine tumors. However, diarrhea is a common adverse event of surufatinib which can affects patients’ quality of life and clinical efficacy. Currently, there are no available animal models to study the cause and treatmen of surufatinib-related diarrhea.

Conference:

Presenting Author: Hu S

Authors: Hu S, Guo Y, Chen Y, Cheng Z, Deng C,

Keywords: Surufatinib, diarrhea, model, rat,

#4089 Peptide receptor radionuclide therapy is effective for hormonal control of carcinoid syndrome

Introduction: Carcinoid syndrome (CS) is the most common functioning syndrome in neuroendocrine tumors (NET) and manifests in symptoms of flushing, diarrhea and fibrosis. Serotonin, a tryptophan metabolite, is considered the principal hormonal mediator of CS. Peptide receptor radionuclide therapy (PRRT) has established antiproliferative effects in NET, but the clinical and biochemical response to PRRT in CS patients is unknown.

Conference:

Presenting Author: Maas C

Authors: Maas C, Mulders M, Mirzaian M, van den Berg S, Brabander T,

Keywords: carcinoid syndrome, neuroendocrine tumor, peptide receptor radionuclide therapy, serotonin,

#4060 Interim safety and exploratory efficacy results of a phase 2, randomised, parallel-group study of oral Paltusotine treatment in subjects with carcinoid syndrome

Introduction: Carcinoid Syndrome (CS) is the most common functional NET syndrome. It is characterized by watery diarrhea or cutaneous flushing. Paltusotine is an investigational once-daily, oral, selective SST2 agonist in development for the treatment of acromegaly and CS. Paltusotine has been shown to maintain IGF-1 control at levels similar to injected depot SRLs.

Conference:

Presenting Author:

Authors: Usiskin K, Chauhan A, Mui C, Dillon J, Fan X,

Keywords: oral, paltusotine, carcinoid syndrome, phase II,

#4058 Carcinoid syndrome caused by pulmonary neuroendocrine tumor liver metastases: A case report

Introduction: Neuroendocrine tumors (NETs) comprise a heterogeneous groups of maliganancies that arise from neuroencrine cells throughout the body and most commonly originate from the small intestine, lung,and rectum. Pulmonary NETs originate from pulmonary neuroendocrine cells that occur as individual cells or small pulmonary neuroendocrine cell. Although carcinoid tumors are considered low or intermediate-grade tumors, they metastasize to regional lymph nodes and distant organs, and the most common sites metastases are the liver and bone.

Conference:

Presenting Author: Tang Y

Authors: Tu R, Tang Y, Wang Y, Zhu Y, Kui X,

Keywords: pulmonary neuroendocrine tumor, liver metastases, Transcatheter Arterial Embolization, chemotherapy,

#3843 VIPoma presenting as chronic diarrhea in a 30-year-old Filipino female

Introduction: Pancreatic neuroendocrine tumors are rare neoplasms that arise in the endocrine tissues of the pancreas. They can secrete a variety of peptide hormones including insulin, gastrin, glucagon, and vasoactive intestinal peptide. Secretory tumors such as vasoactive intestinal polypeptides are rare neuroendocrine pancreatic neoplasms characterized by watery diarrhea, hypokalemia, and hypochlorhydria.

Conference:

Presenting Author: Edejer P

Authors: Edejer P, Mendoza R, Pascasio C, Lin T, Cornelio G,

Keywords: Pancreatic NET, Octreotide, DOTATATE, diarrhea,